Istradefylline
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatic Impairment
Conditions
Hepatic Impairment
Trial Timeline
Aug 1, 2014 → Dec 1, 2014
NCT ID
NCT02256033About Istradefylline
Istradefylline is a phase 1 stage product being developed by Kyowa Kirin for Hepatic Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT02256033. Target conditions include Hepatic Impairment.
What happened to similar drugs?
3 of 18 similar drugs in Hepatic Impairment were approved
Approved (3) Terminated (5) Active (12)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02256033 | Phase 1 | Completed |
| NCT00957203 | Phase 3 | Completed |
| NCT00199381 | Phase 3 | Terminated |
| NCT00955045 | Phase 2/3 | Completed |
Competing Products
20 competing products in Hepatic Impairment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ITF2357 | Biotrial | Phase 1 | 19 |
| GB1211 + Placebo | Comac Medical | Phase 1/2 | 18 |
| ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results) | Idorsia | Phase 1 | 23 |
| Olomorasib | Eli Lilly | Phase 1 | 29 |
| Simufilam | Cassava Sciences | Phase 1 | 19 |
| cisplatin + gemcitabine hydrochloride | Eli Lilly | Phase 3 | 40 |
| exatecan mesylate | Daiichi Sankyo | Phase 2 | 35 |
| DS-3201b | Daiichi Sankyo | Phase 1 | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | 29 |
| Quizartinib | Daiichi Sankyo | Phase 1 | 36 |
| Pexidartinib | Daiichi Sankyo | Phase 1 | 29 |
| Tivantinib + Tivantinib + Tivantinib + Tivantinib | Daiichi Sankyo | Phase 1 | 29 |
| Bocidelpar | Astellas Pharma | Phase 1 | 29 |
| fezolinetant | Astellas Pharma | Phase 1 | 29 |
| enzalutamide | Astellas Pharma | Phase 1 | 29 |
| ASP015K | Astellas Pharma | Phase 1 | 29 |
| ASP2215 | Astellas Pharma | Phase 1 | 29 |
| BPN14770 | Shionogi | Phase 1 | 29 |
| S-217622 | Shionogi | Phase 1 | 29 |
| Lemborexant | Eisai | Phase 1 | 29 |